Phenylephrine on USP-NF
This article was originally published in The Tan Sheet
Executive Summary
Bayer's Consumer Care division is "looking forward to" the inclusion of phenylephrine bitartrate in FDA's monograph for OTC Nasal Decongestant Products following the ingredient's Aug. 1 addition to the U.S. Pharmacopeia's National Formulary, Bayer says in a recent letter to FDA. The monograph amendment would apply to phenylephrine's use in effervescent tablets when used in combination with chlorpheniramine maleate and aspirin, and was proposed by FDA in November 2004 (1"The Tan Sheet" Nov. 8, 2004, p. 11). Phenylephrine's inclusion in the USP-NF is a prerequisite of its addition to the monograph. Bayer, which markets the Alka-Seltzer line of effervescent cough/cold products, submitted comments supporting the monograph amendment in February (2"The Tan Sheet" Feb. 14, 2005, p. 7)...
You may also be interested in...
Decongestant Monograph Definition Expansion Requested By Bayer
FDA should revise its definition of effervescent cold products containing phenylephrine bitartrate (PEB) to make it more flexible, Bayer states in recent comments to FDA
Bayer Bubbles Over Proposed Cough/Cold Monograph Amendment
FDA is proposing to amend the over-the-counter nasal decongestant drugs monograph to include phenylephrine bitartrate (PEB) in effervescent tablets, according to an announcement published in the Federal Register Nov. 2
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.